Laurus Labs reported a strong set of results for the September quarter, with net profit more than doubling year-on-year and revenue and operating earnings comfortably beating CNBC-TV18’s estimates. The pharmaceutical company also announced plans to acquire controlling stakes in two businesses, including a Canada-based biotech firm, and declared an interim dividend of ₹1 per share.
Net profit rose 126.7% year-on-year to ₹442 crore in Q2 FY27, compared with ₹195 crore a year ago. The figure was also well ahead of CNBC-TV18’s poll estimate of ₹354.1 crore.
Revenue from operations grew 33.4% to ₹2,206 crore from ₹1,653.5 crore in the year-ago quarter, surpassing the estimate of ₹2,109.5 crore.
Earnings before interest, tax, depreciation and amortisation (EBITDA) jumped 86% year-on-year to ₹750 crore, against ₹403.3 crore a year earlier. This was higher than the poll estimate of ₹644.4 crore.
EBITDA margin expanded to 34% from 24.4% a year ago, also beating the estimate of 30.5%.
Shares of Laurus Labs were trading 2.14% higher at ₹2,231.80 on the BSE following the earnings announcement.
Laurus Labs to acquire stakes in two companies
Separately, Laurus Labs’ board approved the acquisition of a 52% stake in SI & C Resins Private Limited at a pre-money valuation of ₹30 crore. The company plans to invest ₹32.5 crore in the transaction, which will make SI&C a subsidiary.
SI&C manufactures polymer- and silica-based products for the chemical, pharmaceutical and biotechnology industries. Laurus Labs may also invest up to an additional ₹30 crore in securities issued by SI&C as and when the company requires funds.
The board also approved the acquisition of a 60% stake in Canada-based Galenvs Sciences Inc. at a pre-money valuation of $3.5 million. Laurus Labs proposes to invest $3.75 million, comprising a primary infusion of $2.75 million and a secondary acquisition worth $1 million from the founder shareholder.
Galenvs is a contract research and development organisation specialising in custom oligonucleotide synthesis and functional magnetic nanoparticle technologies for diagnostic and therapeutic applications. Its subsidiary, Galenvs Solutions Inc., will become a step-down subsidiary of Laurus Labs following the acquisition.
₹1 interim dividend declared
Laurus Labs’ board also approved an interim dividend of ₹1 per equity share of ₹2 face value for FY27.
The company has fixed November 6, 2026, as the record date to determine shareholder eligibility. The dividend will be paid on or after November 19, 2026.